Compare BMR & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | PASG |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 26.0M |
| IPO Year | 2021 | 2020 |
| Metric | BMR | PASG |
|---|---|---|
| Price | $1.67 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 43.1K | 30.3K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $0.28 |
| 52 Week High | $4.32 | $20.00 |
| Indicator | BMR | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 37.40 |
| Support Level | $1.57 | $6.71 |
| Resistance Level | $2.10 | $7.72 |
| Average True Range (ATR) | 0.13 | 0.77 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.21 | 16.73 |
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.